[Clinical effect of ceftizoxime suppositories]

Area of Science:

• Pediatric Infectious Diseases
• Pharmacology and Therapeutics
• Antibiotic Administration

Background:

• Evaluating the efficacy and safety of novel drug delivery systems is crucial for patient compliance and treatment outcomes.
• Physically handicapped children often present challenges for conventional oral or intravenous medication administration.
• Ceftizoxime, a third-generation cephalosporin, is a broad-spectrum antibiotic with established efficacy against various bacterial infections.

Observation:

• A study assessed the therapeutic effect of ceftizoxime suppositories (CZX-S) in 8 physically handicapped pediatric patients.
• Infections treated included pharyngitis (6 patients), pneumonia (1 patient), and urinary tract infection (1 patient).
• Clinical assessments were performed to evaluate treatment response and identify any adverse events.

Findings:

• Ceftizoxime suppositories (CZX-S) demonstrated a high clinical success rate, with 'excellent' outcomes in 7 patients and 'good' in 1.
• No adverse reactions or abnormal laboratory findings were associated with the administration of CZX-S.
• The study highlights the utility of CZX-S as a viable therapeutic option in this patient population.

Implications:

• Ceftizoxime suppositories (CZX-S) offer a valuable alternative for treating pediatric infections in physically handicapped children.
• This formulation bypasses the difficulties associated with oral or intravenous routes, potentially improving treatment adherence.
• Further research could explore the broader application of suppository formulations for antibiotics in pediatric care.